Special Editorial
The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities

https://doi.org/10.1016/j.jtho.2021.03.003Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Disclosure: Dr. Osarogiagbon owns patents for a lymph node specimen collection kit; owns stocks in Eli Lilly, Gilead Sciences, and Pfizer; has worked as a paid research consultant for the American Cancer Society, the Association of Community Cancer Centers, AstraZeneca, Eli Lilly, Triptych Healthcare Partners, and Genentech/Roche; and is the founder of Oncobox Device, Inc. Dr. Montuenga reports receiving speaker’ bureau and a research grant from AstraZeneca; is a licensed patent co-holder on Complement in Lung Cancer early detection from AMADIX; and a received a research grant from Bristol-Myers Squibb. Ms. Giroux reports receiving grants from the International Association for the Study of Lung Cancer during the conduct of the study. Dr. Asamura reports receiving personal fees from lecture fees outside of the submitted work. Dr. Rusch reports receiving grants from Genelux, Inc., Genentech; nonfinancial support from Intuitive Surgical; other fees from the National Institute of Health Coordinating Center for Clinical Trials, and other fees from the MARS 2 Trial Data Safety Monitoring Committee outside the submitted work. Dr. Hirsch reports to have participated in scientific advisory boards for Bristol-Myers Squibb, Merck, AstraZeneca, Novartis, Daiichi, Regeneron/Sanofi, OncoCyte, Amgen, and Genentech/Roche; received research funding (through the University of Colorado) from Amgen, Biodesix, Rain Therapeutics, Mersana, and AbbVie; and owns a patent (through University of Colorado) for the work entitled “EGFR protein and Gene Copy Number as Predictive Biomarkers for EGFR Therapy.” The remaining authors declare no conflict of interest.